

CURRICULUM VITAE

JOHN DILLON CARTER, M.D.

ADDRESS:

Office: 2919 W Swann Ave
Suite 402
Tampa, Florida 33609
Phone: 813-696-1681
Fax: 813-696-1703

Website: <https://www.recoveryrheum.com>

Internet: jcarter@recoveryrheum.com

PRESENT APPOINTMENT: Founder & Owner
Recovery Rheum, LLC
2919 W Swann Ave
Suite 402
Tampa, FL 33609
September 16, 2024 - present

BOARD CERTIFICATION: American Board of Rheumatology, 2001, 2011, 2021
American Board of Internal Medicine, 1999
United States Medical Licensing Examination, Step 3, 1997
United States Medical Licensing Examination, Step 2, 1995
United States Medical Licensing Examination, Step 1, 1994

MEDICAL LICENSURE: Florida, ME 0074849

MILITARY STATUS: none

EDUCATION:

Academic College: University of Texas
Austin, Texas
Bachelor of Business Administration, 1990

Premedical Studies: Saint Louis University
Saint Louis, Missouri, 1990-1991
Also worked full time as an oriental rug salesman, 1990-1992

Medical School: Saint Louis University School of Medicine
Saint Louis, Missouri
M.D. Degree, 1996

TRAINING:

Internship: Internal Medicine, University of South Florida
Tampa, Florida
July 1996 – June 1997

Residency: Internal Medicine, University of South Florida
Tampa, Florida
July 1997 – June 1999

Fellowship: Rheumatology, University of South Florida
Tampa, Florida
July 1999 – June 2001

FACULTY APPOINTMENTS:

1. Professor of Medicine, Chief, Division of Rheumatology, Director of Innovative Therapies and Clinical Research, Division of Rheumatology, Department of Internal Medicine, University of South Florida Morsani College of Medicine, Tampa, FL, July 2007 – September 13, 2024
2. Professor of Medicine, University of South Florida College of Medicine, Department of Internal Medicine, Tampa, Florida, August 9, 2014 – September 13, 2024
3. Associate Professor of Medicine, University of South Florida College of Medicine, Department of Internal Medicine, Tampa, Florida, July 1, 2007 – August 8, 2014
4. Assistant Professor of Medicine, University of South Florida College of Medicine, Department of Internal Medicine, Tampa, Florida, July 2001 – June 30, 2007

ADMINISTRATIVE APPOINTMENTS:

Attending Physician, Health Park Rheumatology, Chief of Services, Tampa General Hospital, Tampa, Florida, July 2001 – September 13, 2024
Attending Physician, Rheumatology Section, James A. Haley Veterans Administration Hospital, Tampa, Florida, July 2001 – August 2008

HOSPITAL APPOINTMENTS:

Tampa General Hospital, Tampa, Florida, 2001 – present
James A. Haley Veterans Administration Hospital, Tampa, Florida, 2001 – 2008
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, 2001 – 2014

ORGANIZATIONS:

Resident: American College of Physicians, 1997 - 1999
Member: American College of Rheumatology, 2000 – Present
Member: Florida Society of Rheumatology, 2001 - Present

I. RESEARCH & SCHOLARLY ACTIVITY

GRANTS

Investigator Initiated

1. Regional Grants in Aid (RGIA).
“The Effect of a Low Carbohydrate, High Protein/Fat Diet on Bone Turnover.”
Granting Agency: Procter & Gamble (Investigator Initiated Grant)
Awarded August 2004.
Completed May 2006; published 2006.
Amount Awarded: \$17,675.00
Principal Investigator

2. Unrestricted Fellowship Educational Grant.
“Training Fellows to Perform Clinical Research.”
Granting Agency: Amgen.
Awarded August 2004.
Completed December 2004.
Amount Awarded: \$2500.00
Principal Investigator

3. Investigator Initiated Grants Initiative.
“Male Osteoporosis: Recognition & Treatment.”
Granting Agency: Merck (Investigator Initiated Grant)
Awarded October 2004.
Project completed; manuscript published
Amount Awarded: \$24,835.00
Principal Investigator

4. NIH Exploratory/Developmental Research Grant Award (R21)
“Combination Antimicrobial Therapy as a Treatment for *Chlamydia*-Induced Reactive Arthritis.”
National Institutes of Health (National Institute of Musculoskeletal and Skin Diseases [NIAMS]).
International Multi-Center Trial (4 Study Sites)
Assignment Number: 1 R21 AR053646-01
Start Date May 22, 2006
Stop Date May 21, 2008
Status: Target enrollment met
Amount Awarded: \$415,031.00
Principal Investigator

5. “A Safety Analysis of Oral Prednisone as a Pre-Treatment for Rituximab in Rheumatoid Arthritis.”
Sponsor: Genentech
Amount: \$501,125.00 (with the potential of \$998,945.00 based on study extension)
Project: November, 2006 – January, 2010
Target Enrollment: 50 patients; 44 subjects enrolled
Principal Investigator

6. “MRI and Ultrasound Findings in Patients with Gout and Normal Plain Radiographs.”
Sponsor: TAP Pharmaceuticals
Amount: \$233,650.00
Status: Study completed
Principal Investigator
7. “Shifting the Paradigm of Gout: An Assessment of Chronic Synovial-Based Inflammation and its Role with Serum Urate Levels.”
Sponsor: Takeda Pharmaceuticals
Amount: \$523,372.00
Status: Study completed; manuscripts in press
Principal Investigator
8. “A Retrospective Analysis of the Synovial-Based Inflammation During Inter-Critical Gout Using Quantitative MRI Analysis.”
Sponsor: AstraZeneca
Amount: \$59,100.00
Status: Data analysis underway
Principal Investigator

Pharmaceutical Sponsored Grants/Contracts

1. “A Randomized, Placebo-Controlled, Double-Blind, Parallel Group, International Study to Evaluate the Safety and Efficacy of Rituximab (MabThera/Rituxan) in Combination with Methotrexate, Compared to Methotrexate Monotherapy, in Patients with Active Rheumatoid Arthritis.”
Sponsor: Genentech; Grant: A673Z0; Protocol WA17045-U2973g; Jan 2006 – Sept 2006
Principal Investigator
2. “A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Retreatment with Rituximab in Subjects with Rheumatoid Arthritis Receiving Background Methotrexate.”
Sponsor: Genentech; Grant: A673AE; Protocol U3384g; February 2006 – September 2006
Principal Investigator
3. “A Randomized, Double-blind, Placebo-Controlled Multiple Dose Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Subcutaneous AMG 108 in Subjects With Rheumatoid Arthritis”
Sponsor: Amgen; Grant: 20050168; April 2007 – 2009
Principal Investigator
4. “A randomized, double-blind, parallel group, international study to evaluate the safety and efficacy of ocrelizumab compared to placebo in patients with active rheumatoid arthritis continuing methotrexate treatment.”
Sponsor: Genentech; Grant: WA20494/ACT3985g; January 2007 – 2010
Principal Investigator
5. “A randomized, double-blind, parallel group, international study to evaluate the safety and efficacy of ocrelizumab compared to placebo in patients with active rheumatoid arthritis who have an inadequate response to at least one anti-TNF- α therapy.”
Sponsor: Genentech; Grant: ACT3986g/ WA20495; January 2007 - 2010
Principal Investigator

6. “A Randomized, Double-Blind, Parallel Group, International Study to Evaluate the Safety and Efficacy of Ocrelizumab in Combination With Methotrexate (MTX) Compared to MTX Alone in Methotrexate- Naive Patients With Active Rheumatoid Arthritis.”
Sponsor: Genentech; Grant: ACT3984g; March 2007 - 2010
Principal Investigator
7. “A Phase IIIb, multicenter study with a 12-week double-blind, placebo-controlled randomized period followed by an open-label, extension phase to evaluate the safety and efficacy of certolizumab pegol administered to patients with active rheumatoid arthritis.”
Sponsor: UCB; Grant C87094; June 2008 - 2010
Principal Investigator
8. “A Phase III Randomized, Double-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of Ocrelizumab in Combination with Methotrexate Compared With Infliximab Plus Methotrexate in Patients With Active Rheumatoid Arthritis Currently Responding Inadequately to Etanercept or Adalimumab.”
Sponsor: Genentech; Grant ACT4562g; Dec 2008 – Jan 2010
Principal Investigator
9. “A Multi-Center, Randomized, Double-Blind, Active-Controlled Study of the Safety and Efficacy of Rilonacept Administered Subcutaneously for the Treatment of an Acute Gout Flare.”
Sponsor: Regeneron Pharmaceuticals; IL1T-GA-0814; March 2009 - 2010
Principal Investigator
10. “A Multi-Center, Randomized, Double-Blind, Placebo Controlled Trial of the Safety of Rilonacept for the Prophylaxis of Gout Flares in Patients on Urate Lowering Therapy”
Sponsor: Regeneron Pharmaceuticals; IL1T-GA-0815; March 2009 - 2010
Principal Investigator
11. “A Golimumab Phase 3b, Multicenter, Switch Assessment of Subcutaneous and Intravenous Efficacy in Rheumatoid Arthritis Patients Who Have Inadequate Disease Control Despite Treatment with Etanercept (ENBREL®) or Adalimumab (HUMIRA®)”
Sponsor: Centocor; CNTO148ART3002; Jan 2010- 2015
Principal Investigator
12. “A 12-week, double-blind, randomized, parallel-group, placebo-controlled study of 4 doses of VX-509 in subjects with active rheumatoid arthritis.”
Sponsor: Vertex Pharmaceuticals; Vx 509-09-101; June 2010 – 2014
Principal Investigator
13. “A Phase III, Multi-Center, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients with and inadequate Response to Methotrexate.”
Sponsor: Astra Zeneca; OSKIRA-1; Aug 2010 – 2013
Principal Investigator
14. “A Phase III, Multi-Center, Randomized, Double-Blind, Placebo- Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients with and inadequate Response to a TNF-alpha antagonist.”
Sponsor: Astra Zeneca; OSKIRA-2; Aug 2010 – 2013
Principal Investigator
15. “A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study of two doses of apremilast (CC-10004) in subjects with active psoriatic arthritis.”
Sponsor: Celgene; CC-10004-PSA-003: Sept 2010 – 2017
Principal Investigator

16. “A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients with Systemic Lupus Erythematosus (SLE).”
Sponsor: Eli Lilly and Company, H9B-MC-BCDS: Jan 2011- 2015
Principal Investigator
17. “A Phase 3, Multicenter, Open-Label, Extension Study To Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects (EMBODY 4).”
Sponsor: UCB Inc, #SL0012: Jan 2011 – 2014.
Principal Investigator
18. “A multi-center, open-label, single-arm study to evaluate the safety of administering rituximab at a more rapid infusion rate in patients with rheumatoid arthritis.”
Sponsor: Genentech, Inc; ML25641: Jan 2012 – 2016.
Principal Investigator
19. “A randomized, double-blind, placebo-controlled study of secukinumab to demonstrate the efficacy at 24 weeks and to assess the safety, tolerability and long-term efficacy up to 2 years in patients with active rheumatoid arthritis who have and inadequate response to anti-TNF agents.”
Sponsor: Novartis, AIN457F: Feb 2012 – 2018.
Principal Investigator
20. “A randomized, controlled study of sarilumab and methotrexate (MTX) versus etanercept and MTX in patients with rheumatoid arthritis (RA) and an inadequate response to 4 months of treatment with adalimumab and MTX.”
UCB Pharmaceuticals; EFC11574
Dates: 2013 – 2018
Principal Investigator
21. “A PHASE 3B, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF APREMILAST (CC-10004) MONOTHERAPY IN SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS.”
Celgene; PSA-006
Dates: 2013 – 2019
Principal Investigator
22. “A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 24-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease Modifying Antirheumatic Drug-Naive Patients with Active Psoriatic Arthritis.”
Eli Lilly; I1F-MC-RHAP
Dates: 2013 – 2015
Principal Investigator
23. “A Phase 2 study assessing the effect of Pomalidomide in Scleroderma patients with interstitial lung disease.”
Celgene; CC-4047
Dates: 2013 – 2015
Principal Investigator
24. 2014 – present: I have been the PI on >20 different pharmaceutical sponsored multi-center trials (not listed here but can be obtained from the Office of Clinical Research)

Other Active Research

1. “Intracellular Localization and Activation of P38-MAP Kinase in Synovial Fluid Neutrophils obtained from Patients with Inflammatory Arthritis.”
May, 2005 - 2007
Co-Investigator
2. “Evaluation of Pro-Inflammatory Matrix Molecules as Biomarkers for Progression of Vascular Lesions In Systemic Lupus Erythematosus Using a Confocal Laser Microscope.”
December, 2005 - 2007
Principal Investigator
3. “The Incidence of Malignancies in Patients Taking Tumor Necrosis Factor-alpha Antagonists.”
June 1, 2006 - 2008
Principal Investigator
4. “CCR-5 delta 32 Mutation and its Relationship to the Development of Salmonella Induced Reactive Arthritis.”
July 3, 2006 - 2010
Principal Investigator (laboratory testing funded by Co-PI, Alan P Hudson, PhD; Wayne State University)
5. “CCR-5 delta 32 Mutation and its Relationship to the Development of Chlamydia-Induced Reactive Arthritis.”
July 3, 2006 - 2010
Principal Investigator (laboratory testing funded by Co-PI, Alan P Hudson, PhD; Wayne State University)
6. “The Effect of Tumor Necrosis Factor-alpha Inhibition on Persistent Chlamydia in Human Mononuclear Cells.”
July 10, 2006 - 2018
Principal Investigator (laboratory testing funded by Co-PI, Alan P Hudson, PhD; Wayne State University)

Research Preceptorships

1. Preceptor: Abdul L. Lodhi; M.D. (Rheumatology Fellow)
Title of Project: “*Determining Rheumatologists’ Accuracy at Assessing Functional Disability in Rheumatoid Arthritis Patients by Using the Health Assessment Questionnaire – Disability Index (HAQ-DI).*”
July 2002 – June 2004
2. Preceptor: Erica Traina, MSI
Title of Project: “*Determining Rheumatologists’ Accuracy at Assessing Functional Disability in Rheumatoid Arthritis Patients by Using the Health Assessment Questionnaire – Disability Index (HAQ-DI).*”
June 2004 – July 2004
3. Preceptor: Farah Sultan, MSI
Title of Project: “*Male Osteoporosis: Recognition & Treatment.*”
June 2005 – July 2005
4. Preceptor: Shalini Patel, MS1
Title of Project: “*Male Osteoporosis: Recognition & Treatment.*”
June 2005 – July 2005

5. Preceptor: Bradley Weitzner, M.D. (Rheumatology Fellow)
Title of Project: *“Evaluation of Pro-Inflammatory Matrix Molecules as Biomarkers for Progression of Vascular Lesions In Systemic Lupus Erythematosus Using a Confocal Laser Microscope.”*
July 2004 – June 2006
6. Preceptor: Margaux Hemstreet, MSI
Title of Project: *“The Incidence of Thromboembolic Events in Patients Taking TNF-alpha Antagonists.”*
June 2006 – July 2006
7. Preceptor: Humayun Beg, M.D. (Rheumatology Fellow)
Title of Project: *“CCR-5 delta 32 Mutation and its Relationship to the Development of Salmonella Induced Reactive Arthritis.”*
June 2006 – 2008
8. Preceptor: Natalie Brown, M.D. (Rheumatology Fellow)
Title of Project: *“Tumor Necrosis Factor-alpha Antagonists and the Induction of Autoantibodies in the setting of Rheumatoid Arthritis.”*
February 2005 – 2007
9. Preceptor: Jason Guthrie, M.D. (Rheumatology Fellow)
Title of Project: *“CCR-5 delta 32 Mutation and its Relationship to the Development of Chlamydia-Induced Reactive Arthritis.”*
July 2006 – 2008
10. Preceptor: Aasim Rehman, M.D. (Rheumatology Fellow)
Title of Project: *“CCR-5 delta 32 Mutation and its Relationship to the Development of Chlamydia-Induced Reactive Arthritis.”*
July 2008 – 2010
11. Preceptor: Vanessa Osting, D.O. (Rheumatology Fellow)
Title of Project: *“A randomized prospective open-label comparison of two Vitamin D3 repletion strategies in Vitamin D deficient patients.”*
July 2008 – 2010
12. Preceptor: Ernesto Rodriguez, M.D.
Title of Project: *“Shifting the Paradigm of Gout: An Assessment of Chronic Synovial-Based Inflammation and its Role with Serum Urate Levels.”*
July 2009 - 2011
13. Preceptor: Abie Alias, D.O.
Title of Project: *“Ultrasound Detection of Monosodium Urate Crystal Deposits on Hyaline Cartilage and its Relationship to Serum Urate Level.”*
July 2009 – 2011
14. Preceptor: Julio Gonzalez, M.D.
Title of Project: *“Assessment of a correlation between osteoarthritis of the cervical spine and hands.”*
July 2010 – 2012
15. Preceptor: Charles Degenhardt, M.D.
Title of Project: *“Does patient-rheumatologist interaction alter a patient’s global assessment of their disease?”*
July 2010 – 2012
16. Preceptor: Amir Agha, M.D.
Title of Project: *“Assessment of the Prevalence of Gout in Patients with Spondyloarthritis.”*
July 2011 – 2013
17. Preceptor: Ilias Oikonomopoulos, M.D.

- Title of Project: "Analysis Correlation of CRP and ESR in Patients with RA and PsA."
July 2012 – 2014
18. Preceptor: Anna Muchnik, D.O.
Title of Project: "Comparison of PFTs vs. Echo at predicting pulmonary HTN in patients with Scleroderma."
July 2012 - 2014
19. Preceptor: Alicia Fierro, D.O.
Title of Project: "Assessment of the Prevalence of Gout in Patients with Spondyloarthritis."
July 2013 - 2015
20. Preceptor: Catherine Garcia, M.D.
Title of Project: "Increasing the Capture of patients with non-radiographic SpA with MRI."
July 2013 – 2015
21. Preceptor: Marielys Figueroa, M.D.
"Improving Glucocorticoid Induced Osteoporosis Screening and Management in Patients with Rheumatic Diseases Using the 2017 ACR Guidelines."
July 2019 - 2021
22. Preceptor: Silera Balbuena, M.D.
Title of Project: "Clinical Outcomes of COVID-19 Vaccination and Booster in Patients with Autoimmune Inflammatory Rheumatic Disease."
January 2021 - 2022

II. FORMAL TEACHING

1. Physical Diagnosis of the Musculoskeletal System.
Course #: BMS-6830B
University of South Florida
Second Year Medical Students
I personally designed and taught the course.
1999 – 2004
2. Clinical Rheumatology Elective
Course #: MEL-8339
University of South Florida
Fourth Year Medical Student Elective
3. Rheumatology Exam Review Course
Course #: BCC-7144
University of South Florida
Third Year Medical Student Internal Medicine Clerkship
2001 – 2005.
4. First Year Medical Student Longitudinal Clinical Experience Mentor Program (LCME).
Course #: BMS-6941-001
University of South Florida.
2002 – present.
5. Second Year Medical Student Longitudinal Clinical Experience Mentor Program (LCME).
Course #: BMS-6941-002
University of South Florida.
2002 – present.
6. Summer Research Elective for First Year Medical Students.
University of South Florida.
2004 – 2007.
7. Physical Diagnosis of the Musculoskeletal System.
Course #: BMS-6830B
University of South Florida
Second Year Medical Students
2004 - 2008
8. Skin and Bones Fourth Year Medical Student Clerkship
Course #: BCC-8116
University of South Florida
2006 – present.
9. Colloquium Years 1 & 2
Course #: BMS 6920 002
University of South Florida
2009 – 2010

III. BIBLIOGRAPHY

PUBLICATIONS (Peer Reviewed Journals):

1. **Carter JD**, Cutolo EP, Behnke RH, Adelman HM. Pulmonary Infiltrates in an Elderly Man. *Hospital Practice*. 34(8):21-4,1999.
2. **Carter JD**, Kanik KS, Valeriano J. Neck Mass in a Rheumatoid Arthritis Patient Taking Etanercept. *Journal of Clinical Rheumatology*. 6(2):80-1, 2000.
3. **Carter JD**, Vasey FB, Valeriano-Marcet J, Kanik KS. “G” Stands for Gout. *Arthritis and Rheumatism*. 43(6):1418, 2000.
4. **Carter JD**, Kanik KS, Vasey FB, Valeriano-Marcet J. Dermatomyositis with Normal Creatine Kinase and Elevated Aldolase Levels (letter). *Journal of Rheumatology*. 28(10):2366-7, 2001.
5. **Carter JD**, Vasey FB, Kanik KS, Valeriano-Marcet. Polymyalgia Rheumatica and Temporal Arteritis with Sacroiliitis and Osteitis Pubis. *Journal of Clinical Rheumatology*. 7(4):261-4, 2001.
6. **Carter JD**, Valeriano-Marcet J, Kanik KS, Vasey FB. ANA Negative Drug Induced Lupus Caused by Lisinopril. *Southern Medical Journal*. 94(11):1122-3, 2001.
7. **Carter JD**, Vasey FB. Psoriatic Arthritis: Genetics, Immunology, and Therapies (Editorial). *Journal of Clinical Rheumatology*. 7(6):363-5, 2001.
8. **Carter JD**, Valeriano J, Vasey FB. Reply to: Dermatomyositis with Normal Creatine Kinase and Elevated Aldolase Levels (letter). *Journal of Rheumatology*. 29(10):2242-3,2002.
9. Valeriano J, **Carter JD**, Vasey FB. Soft Tissue Infections (Review). *Rheumatic Disease Clinics of North America*. 29(1):77-88, 2003.
10. McIlwain L, **Carter JD**, Bin-Sagheer S, Vasey FB, Nord J. Hypersensitivity Vasculitis with Leukocytoclastic Vasculitis Secondary to Infliximab. *Journal of Clinical Gastroenterology*. 36(5):411-3, 2003.
11. **Carter JD**, Warner E. Tumoral Calcinosis in a patient with Sarcoidosis. *Arthritis & Rheumatism*. 48(6):1770, 2003.
12. **Carter JD**, Valeriano J, Vasey FB. A Case of Crohn’s Disease Worsened by Anakinra. *Journal of Clinical Rheumatology*. 9(4):275-6, 2003.
13. **Carter JD**, Bogнар B, Valeriano J, Vasey FB. Refractory neurosarcoidosis: a dramatic response to Infliximab. *American Journal of Medicine*. 117(4):277-9, 2004.
14. **Carter JD**, Valeriano J, Vasey FB. A Prospective, Randomized 9-Month Comparison of Doxycycline vs. Doxycycline and Rifampin in Undifferentiated Spondyloarthritis – with Special Reference to *Chlamydia*-Induced Arthritis. *Journal of Rheumatology*. 31(10):1973-80, 2004.
15. Lodhi A, **Carter JD**, Valeriano J, Vasey FB. Can We Classify Psoriatic Arthritis? (editorial). *Seminars in Arthritis & Rheumatism*. 34(3):571-2, 2004.

16. **Carter JD.** Treatment of Relapsing Polychondritis with a Tumor Necrosis Factor Inhibitor. *Journal of Rheumatology.* 32(7):1413, 2005.
17. **Carter JD,** Valeriano J, Vasey FB. Antimicrobials for the Treatment of Chlamydia-Induced Reactive Arthritis. *Annals of the Rheumatic Diseases.* 64(3):512-3, 2005.
18. **Carter JD,** Valeriano J, Vasey FB. Tumor Necrosis Factor Inhibition and VATER Association: A Causal Relationship? *Journal of Rheumatology.* 33(5):1014-7, 2006.
19. Cruse LM, Valeriano J, Vasey FB, **Carter JD.** Prevalence of Evaluation and Treatment of Glucocorticoid-Induced Osteoporosis in Men Hospital. *Journal of Clinical Rheumatology.* 12(5):221-5, 2006.
20. **Carter JD,** Valeriano J, Vasey FB. Hydroxychloroquine as a Treatment for Atrophoderma of Pasini and Pierini. *International Journal of Dermatology.* 45(10):1255-6, 2006.
21. **Carter JD,** Vasey FB, Valeriano J. The Effect of a Low Carbohydrate Diet on Bone Turnover. *Osteoporosis International.* 17(9):1398-1403, 2006.
22. Vasey FB, **Carter JD.** Intestinal Flora and Psoriatic Arthritis. *Journal of Rheumatology.* 33(10):2099, 2006.
23. **Carter, JD,** Espinoza LR. The Interplay of Environment and Host Response in Reactive Arthritis: Can We Intervene? *Future Rheumatology.* 1(6):717-27, 2006.
24. **Carter, JD.** TNF-alpha Inhibition Causing Psoriasis? A More Plausible Explanation Exists. *Annals of the Rheumatic Diseases.* 65(12):1680, 2006.
25. **Carter JD.** Reactive Arthritis: Defined Etiologies, Emerging Pathophysiology, and Elusive Treatment. *Infectious Disease Clinics of North America.* 20(4):827-47, 2006.
26. **Carter JD,** Lodhi A, Nagda SR, Ricca L, Ward C, Traina E, Thompson ZJ, Huang x, Valeriano J, Vasey FB. Determining Rheumatologists' Accuracy at Assessing Functional Disability in Rheumatoid Arthritis Patients by Using the Health Assessment Questionnaire – Disability Index (HAQ-DI). *Journal of Rheumatology.* 34(5):958-63, 2007.
27. Brown NA, **Carter JD.** Urticarial Vasculitis. *Current Rheumatology Reports.* 9(4):312-9, 2007.
28. **Carter JD.** Functional Disability Determination of the Rheumatoid Arthritis Patient: A Failing System. Touch Briefings, US Musculoskeletal Review. Issue II:26-7, 2007.
29. McKinley J, Vasey F, McMillen A, **Carter J,** Brady P. Joint Observations with Lessons for Rheumatologists and Gastroenterologists. *Inflammatory Bowel Disease* 14(5):730-1, 2008.
30. **Carter JD,** Patel S, Sultan FL, Thompson ZJ, Hemstreet M, Sterrett A, Carney G, Murphy N, Huang Y, Valeriano J, Vasey FB. The Recognition and Treatment of Vertebral Fractures in Males with Chronic Obstructive Pulmonary Disease. *Respiratory Medicine.* 102(8):1165-72, 2008. Epub 2008 Jun 18.

31. **Carter JD**, Gerard HC, Hudson AP. Psoriasiform Lesions Induced by TNF Antagonists: A Skin-Deep Medical Conundrum. *Annals of the Rheumatic Diseases* 67(8):1181-3, 2008. Epub 2008 Feb 25.
32. Baag AA, Vale FL, **Carter JD**, Rojiani AM. Granulomatosis with CNS Involvement: A Neuroimaging Clinicopathologic Correlation. *Journal of Neuroimaging* Epub 2008 Apr 3.
33. Shetty A, Marcum C, Glass LF, **Carter JD**. Successful Treatment of Pemphigus Vulgaris with the TNF-alpha Antagonist Etanercept in 4 Patients. *Journal of Drugs in Dermatology* 2009;8(10):940-3.
34. **Carter JD**, Ladhani A, Ricca LR, Valeriano J, Vasey FB. A Safety Assessment of TNF Antagonists During Pregnancy: A Review of the FDA Database. *Journal of Rheumatology*. 2009;36(3):635-41.
35. Ingram S, McKinley JM, Vasey F, **Carter JD**, Brady PG. Are Inflammatory Bowel Disease and Pouchitis a Reactive Enteropathy to Group D Streptococci (Enterococci)? *Inflammatory Bowel Disease* 2009;15(11):1609-10.
36. **Carter JD**, Gérard HC, Espinoza LR, Ricca LR, Valeriano-Marcet J, Snelgrove J, Oszust C, Vasey FB, Hudson AP. Chlamydiae as Etiologic Agents for Chronic Undifferentiated Spondyloarthritis. *Arthritis & Rheumatism* 2009;60(5):1311-1316.
37. Gerard HC, Whittum-Hudson JA, **Carter JD**, Hudson AP. Molecular Biology of Infectious Agents in Chronic Arthritis. *Rheumatic Disease Clinics of North America* 2009;35(1):1-19.
38. **Carter JD**, Hudson AP. Reactive Arthritis: Clinical Aspects and Medical Management. *Rheumatic Disease Clinics of North America* 2009;35(1):21-44.
39. Breglia M, **Carter JD**. Atypical Insufficiency Fracture of the Tibia Associated with Long-Term Bisphosphonate Therapy. *Journal of Clinical Rheumatology* 2010;16(2):76-8
40. **Carter JD**, Kedar RP, Anderson SR, Osorio AH, Albritton NL, Gnanashanmugam S, Valeriano-Marcet J, Vasey FB, Ricca LR. MRI and Ultrasound Findings in Patients with Gout and Normal Plain Radiographs. *Rheumatology (Oxford)* 2009;48(11):1442-6.
41. **Carter JD**, Hudson AP. Time to Prove the Infective Etiology of Ankylosing Spondylitis and Related Spondyloarthritides. *Arthritis & Rheumatism* 2009;60(11):3520-1.
42. Stanich JA, **Carter JD**, Whittum-Hudson JA, Hudson AP. Rheumatoid arthritis: disease or syndrome? *Open Access Rheumatology: Research and Reviews* 2009;1(12).
43. Gérard HC, Stanich JA, Oszust C, Whittum-Hudson JA, **Carter JD**, Schumacher HR, Hudson AP. Functional CCR5 receptor protects arthritis patients from high synovial burden of infecting Chlamydia trachomatis. *American Journal of Medical Sciences* 2010;340(6):448-51. Aug 31 epub ahead of print.
44. Gérard HC, Stanich JA, Whittum-Hudson JA, Schumacher HR, **Carter JD**, Hudson AP. Patients with Chlamydia-Induced Arthritis have Ocular (trachoma), Not Genital, Serovars of *C trachomatis* in Synovial Tissue. *Microbial Pathogenesis* 2010;48(2):62-8.

45. **Carter JD**, Espinoza LR, Inman RD, Sneed KB, Ricca LR, Vasey FB, Valeriano J, Stanich JA, Oszust C, Gérard HC, Hudson AP. Combination Antibiotics as a Treatment for Chronic *Chlamydia*-Induced Reactive Arthritis. *Arthritis & Rheumatism* 2010;62(5):1298-1307.
46. **Carter JD**. Treating Reactive Arthritis: Insights for the Clinician. *Therapeutic Advances in Musculoskeletal Disease* 2010;2(1):45-54.
47. Osting VC, **Carter JD**. A Safety Assessment of the TNF-antagonists During Pregnancy. *Expert Opinion on Drug Safety* 2010;9(3):421-9.
48. **Carter JD**. Bacterial Agents in Spondyloarthritis: A Destiny from Diversity? *Best Practice & Research: Clinical Rheumatology* 2010;24(5):701-14.
49. Gerard HC, Whittum-Hudson JA, **Carter JD**, Hudson AP. The Pathogenic Role of *Chlamydia* in Spondyloarthritis. *Current Opinion in Rheumatology* 2010:363-7.
50. **Carter JD**, Hudson AP. The Evolving Story of *Chlamydia*-Induced Reactive Arthritis. *Current Opinion in Rheumatology* 2010;22(4):424-30.
51. **Carter JD**, Hudson AP. *Chlamydia*-Induced Reactive Arthritis: The Potential for Eradication (Editorial). *International Journal of Clinical Rheumatology* 2010;5(5):505-8.
52. Shetty A, **Carter JD**. Sarcoidosis Mimicking Lymphoma on FDG-PET Imaging. *Radiology Case Reports* 2011;6(2):1-4.
53. Sterrett AG, Bateman H, Guthrie J, Rehman A, Osting V, **Carter JD**, Ricca LR, Valeriano J. Using Simulators to Teach Medical Students, Internal Medicine Residents, and Rheumatology Subspecialty Residents Arthrocentesis. *Journal of Clinical Rheumatology* 2011;17(3):121-3.
54. **Carter JD**, Gerard HC, Whittum-Hudson JA, Hudson AP. Combination antibiotics for the treatment of *Chlamydia*-induced Reactive Arthritis: is a cure in sight? *International Journal of Clinical Rheumatology* 2011;6(3):333-45.
55. **Carter JD**, Inman RD. *Chlamydia*-induced reactive arthritis: hidden in plain sight? *Best Practice & Research: Clinical Rheumatology* 2011;25:359-74.
56. **Carter JD**, Inman RD, Whittum-Hudson JA, Hudson AP. Chlamydia and Chronic Arthritis. *Annals of Medicine* 2012;44(8):784-92.
57. Gerard HC, **Carter JD**, Whittum-Hudson JA, D, Hudson AP. *C. trachomatis* Is Present And Metabolically Active During The Remitting Phase In Synovial Tissues From Patients With Chronic *Chlamydia*-Induced Reactive Arthritis. *American Journal of Medical Sciences* 2013;346(1):22-5.
58. **Carter JD**, Zarabadi SA, Ricca LR, McNeil A, Valeriano-Marcet J, Vasey FB, Sebba AI. A Safety Analysis of Oral Prednisone as a Pre-Treatment for Rituximab in Rheumatoid Arthritis. *Clinical Rheumatology* 2012;31(11):1605-10.

59. **Carter JD**, Gerard HC, Whittum-Hudson JA, Hudson AP. The molecular basis for disease phenotype in chronic *Chlamydia*-induced arthritis. *International Journal of Clinical Rheumatology* 2012;7(6):627-40.
60. Terkeltaub RA, Schumacher HR, **Carter JD**, Baraf HS, Evans RR, Wang J, King-Davis S, Weinstein SP. Riloncept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator. *Arthritis Research & Therapy* 2013;15(1):R25. [Epub ahead of print]
61. **Carter JD**, Rehman A, Guthrie JP, Gerard HC, Stanich J, Hudson AP. A Prospective Analysis of the Attack Rate of *Chlamydia*-Induced Reactive Arthritis and the Effect of CCR5-Delta-32 Mutation. *Journal of Rheumatology* 2013;40(9):1578-82.
62. Fischbach KE, Coe B, Radwan M, Gonzalez J, **Carter JD**, Rumbak MJ. Macrophage Activation Syndrome in a Patient with Adult Still's Disease Following Rituximab: presenting with 'pseudo-septic shock'. *ICU Director* 2013;4(5):248-51.
63. Genovese M, Fleischman R, Furst D, Janssen N, **Carter JD**, Dasgupta B, Pitzalis, Durez P, Bryson J, Duncan B, Zhu W, Kretsos K. Efficacy and Safety of Olokizumab in Rheumatoid Arthritis Patients with an Inadequate Response TNF Inhibitor Therapy: Outcomes of a Phase IIb Study. *Annals of the Rheumatic Diseases* 2014;73(9):1607-15.
64. Garcia C, **Carter JD**, Lin YC. The Potential Causality of the Microbiome and Infectious Pathogens in Primary Vasculitis. *Current Clinical Microbiology Reports* 2014;1:73-80.
65. **Carter JD**, Patelli M, Anderson SR, Prakash N, Aydelott R, Rodriguez EJ, Bateman H, Sterrett AG, Valeriano J, Ricca LR. An MRI Assessment of Chronic Synovial-Based Inflammation in Gout and its Correlation with Serum Urate Levels. *Clinical Rheumatology* 2015;34(2):345-51.
66. **Carter JD**, Patelli M, Anderson SR, Prakash N, Rodriguez EJ, Ricca LR. A MRI Assessment of the Response of Chronic, Occult, Synovial-Based Inflammation of Gout to Serum Urate Lowering Therapy. *Journal of Rheumatic Diseases and Treatment* 2015.
67. Sapir T, Rusie E, Greene L, Yazdany J, Robbins ML, Ruderman EM, **Carter JD**, Patel B, Moreo K. Influence of Continuing Medical Education on Rheumatologists' Performance on National Quality Measures for Rheumatoid Arthritis. *Rheumatol Ther.* 2015 Dec;2(2):141-151.
68. Chen X, Eksioglu EA, **Carter JD**, Fortenbery N, Donatelli SS, Zhou J, Liu J, Yang L, Gilvary D, Djeu J, Wei S. Inactivation of DAP12 in PMN inhibits TREM1-mediated activation in rheumatoid arthritis. *PLoS One.* 2015 Feb 2;10(2):e0115116
69. **Carter JD**, Hudson AP. Recent advances and future directions in understanding and treating Chlamydia-induced reactive arthritis. *Expert Rev Clin Immunol.* 2017 13(3): 196-207
70. Raturi R, Patel AA, **Carter JD**. Two cases demonstrating thalidomide's efficacy in refractory lupus nephritis. *Clin Rheum* 2017 36(3):725-72

Published Books or Book Chapters:

1. **Carter JD**. Methotrexate. In Adelman HM. *Rheumatology Questions and Answers*. Merit Publishing International. Surrey, England. 2008:199-205.

2. **Carter JD.** Hydroxychloroquine. In Adelman HM. Rheumatology Questions and Answers. Merit Publishing International. Surrey, England. 2008:205-8.
3. **Carter JD.** Calcitonin. In Adelman HM. Rheumatology Questions and Answers. Merit Publishing International. Surrey, England. 2008:229-33.
4. **Carter JD.** Leflunomide. In Adelman HM. Rheumatology Questions and Answers. Merit Publishing International. Surrey, England. 2008:210-4.
5. **Carter JD.** Etanercept. In Adelman HM. Rheumatology Questions and Answers. Merit Publishing International. Surrey, England. 2008:214-20.
6. **Carter JD.** Infliximab. In Adelman HM. Rheumatology Questions and Answers. Merit Publishing International. Surrey, England. 2008:220-3.
7. **Carter JD.** Adalimumab. In Adelman HM. Rheumatology Questions and Answers. Merit Publishing International. Surrey, England. 2008:223-6.
8. Guthrie JP, **Carter JD.** Reactive Arthritis (a monograph written for an online textbook). British Medical Journal Publishing; London, England. 2008 (updated 2009, 2010, 2011)
9. **Carter JD.** Lupus Panniculitis. In Valeriano-Marcet J & Bateman H. Visual Diagnosis: Self Tests on Rheumatology. 2009:52-54.
10. **Carter JD.** Pustular Psoriasis and TNF Antagonists. In Valeriano-Marcet J & Bateman H. Visual Diagnosis: Self Tests on Rheumatology. 2009:55-58.
11. **Carter JD.** Hypersensitivity Vasculitis. In Valeriano-Marcet J & Bateman H. Visual Diagnosis: Self Tests on Rheumatology. 2009:65-70.59-64.
12. **Carter JD.** CNS Manifestations of Wegener's Granulomatosis. In Valeriano-Marcet J & Bateman H. Visual Diagnosis: Self Tests on Rheumatology. 2009:71-76.
13. **Carter JD.** Neurosarcoidosis. In Valeriano-Marcet J & Bateman H. Visual Diagnosis: Self Tests on Rheumatology. 2009:77-82.
14. **Carter JD.** Reactive Arthritis. In Fitzpatrick's Dermatology in General Medicine (8th Edition). McGraw Hill Publishing. Philadelphia, PA. 2012; Chapter 20:243-52.
15. **Carter JD,** Hudson AP. Spondyloarthritis – Reactive Arthritis. In Encyclopedia of Medical Immunology (MacKay, Ian, Rose, Noel R, Eds). Springer Science Business Media. Berlin, Germany. In press.
16. **Carter JD,** Oikonomopoulis I. Acute Rheumatic Fever. In inPractice Rheumatology (Borenstein D, Editor). inPractice Resources, LLC.
17. **Carter JD.** Reactive Arthritis. In inPractice Rheumatology (Borenstein D, Editor). inPractice Resources, LLC.; 2016

18. **Carter JD**, Hudson AP. Undifferentiated Spondyloarthritis. In Kelley's Textbook of Rheumatology (10th Edition). WB Saunders & Co, Philadelphia, PA. 2016
19. **Carter JD**, Hudson AP. Reactive Arthritis. In Kelley's Textbook of Rheumatology (10th Edition). WB Saunders & Co, Philadelphia, PA. 2016
20. **Carter JD**, Taurog JD. Psoriatic Arthritis. In Harrison's Principles of Internal Medicine (19th Edition). McGraw Hill Publishing, Philadelphia, PA. 2017
21. **Carter JD**, Taurog JD. Reactive Arthritis. In Harrison's Principles of Internal Medicine (19th Edition). McGraw Hill Publishing, Philadelphia, PA. 2017
22. **Carter JD**. Reactive Arthritis: The Hidden Bacterial Connection. In The Human Microbiota and Chronic Disease – Dysbioses as a Cause of Human Pathology. Wiley Blackwell Publishing, Hoboken, NJ. 2017
23. Leirisola-Repo M, **Carter JD**. Infection and Spondyloarthritis. In Inman and Sieper's Oxford Textbook of Axial Spondyloarthritis. Oxford University Press. 2017
24. **Carter JD**. Reactive Arthritis. In BMJ Best Practices. BMA House, BMJ Publishing Group. 2020
25. **Carter JD**. Clinical Overview: Reactive Arthritis. In Point of Care: Clinical Solutions. Elsevier Publishing Group. In press
26. **Carter JD**, Hudson AP. Undifferentiated Spondyloarthritis. In Kelley's Textbook of Rheumatology (11th Edition). WB Saunders & Co, Philadelphia, PA. In press
27. **Carter JD**, Hudson AP. Reactive Arthritis. In Kelley's Textbook of Rheumatology (11th Edition). WB Saunders & Co, Philadelphia, PA. In press

Abstracts Presented/Published:

1. **Carter JD**, Mills CR, Valeriano J, Kanik KS and Vasey FB: Preliminary 6 month results of a prospective comparison of doxycycline vs. doxycycline and rifampin in undifferentiated spondyloarthritis. *Arthritis and Rheumatism*. 44(9 supplement):S92(235),2001. American College of Rheumatology National Convention; San Francisco, CA; October 22, 2001. University of South Florida Research Day; Tampa, FL; February 24, 2002.
2. Valeriano-Marcet J, Johnson T, Lowenstein M, Dacchille B, Stephenson A, **Carter JD**, Vasey FB: Osteoporosis Risk Assessment Tool (ORAT) Assists Clinicians in Selecting Postmenopausal Women for DXA Testing. ASBMR 25th Annual Meeting, September 19-23, 2003.
3. Kirzhner I, Howell T, Rhee D, Warman M, Sandy J, **Carter JD**, Plaas A. Disulfide Bonded Multimers of Lubricin in Normal Synovial Fluid – Synthesis and Assembly by Synovial Lining Cells. Cartilage Innovation Summit; Cleveland Clinic, May 2005.

4. Lodhi A, Valeriano J, Vasey FB, **Carter JD**. Rheumatologists' Ability to Predict Functional Disability in Rheumatoid Arthritis Patients by Using the Health Assessment Questionnaire (HAQ). American College of Rheumatology National Convention, San Diego, CA; November 11-17, 2005.
University of South Florida Research Day, Tampa, FL; February 23, 2006
5. Brown NA, Vasey FB, **Carter JD**. TNF-alpha Antagonists and the Induction of Autoantibodies. University of South Florida Research Day, Tampa, FL; February 23, 2007.
Rheumatology on the Beach, Destin, FL; March 28, 2007.
6. Guthrie JP, Oszust C, Hudson AP, **Carter JD**. CCR-5 Delta 32 Mutation and its Relationship to the Development of *Chlamydia*-Induced Reactive Arthritis. Rheumatology on the Beach, Destin, FL; March 28, 2007.
7. **Carter JD**, Espinoza LR, Inman RD, Seleznick M, Sneed K, Ricca L, Valeriano J, Vasey FB, Oszust C, Snelgrove J, Hudson AP. An Evaluation of the Utility of PBMC PCR Testing for *Chlamydia* in Subjects with Suspected Chronic *Chlamydia*-Induced Reactive Arthritis. 71st American College of Rheumatology National Annual Scientific Meeting. Boston, MA, November 6-11, 2007. ARTHRITIS RHEUM 2007;Vol.56, No.9:S540. (Accepted as a Presentation at Concurrent Session).
8. **Carter JD**, Espinoza LR, Inman RD, Seleznick M, Sneed K, Ricca L, Valeriano J, Vasey FB, Oszust C, Snelgrove J, Gerard H, Hudson AP. A Comparison of the Phenotypic Manifestations of *Chlamydia trachomatis* vs. *Chlamydia pneumoniae*-Induced Reactive Arthritis. 71st American College of Rheumatology National Annual Scientific Meeting. Boston, MA, November 6-11, 2007. ARTHRITIS RHEUM 2007;Vol.56, No.9:S541. (Accepted as a Presentation at Concurrent Session).
9. **Carter JD**, Ladhani A, Ricca L, Valeriano J, Vasey FB. A Safety Assessment of the TNF Antagonists During Pregnancy: A Review of the FDA Database. 71st American College of Rheumatology National Annual Scientific Meeting. Boston, MA, November 6-11, 2007. ARTHRITIS RHEUM 2007;Vol.56, No.9:S286. **Plenary Session Presentation.**
10. Hudson AP, Oszust C, Guthrie JP, Whittum-Hudson JA, Snelgrove J, **Carter JD**, Schumacher HR, Gerard HC. Functional CCR5 Receptor Protects From High Synovial *Chlamydia trachomatis* Burden but Differentially Protects Against Induction of Inflammatory Arthritis in ReA and UO Patients. 71st American College of Rheumatology National Annual Scientific Meeting. Boston, MA, November 6-11, 2007. ARTHRITIS RHEUM 2007;Vol.56, No.9:S619.
11. Hudson AP, Schumacher HR, Whittum-Hudson JA, **Carter JD**, Gerard HC. Patients Infected with *Chlamydia Trachomatis* Frequently Have Ocular, Not Genital, Serovars of the Organism in the Synovial Tissue. 71st American College of Rheumatology National Annual Scientific Meeting. Boston, MA, November 6-11, 2007. ARTHRITIS RHEUM 2007;Vol.56, No.9:S619.
12. Beg H, **Carter JD**, Vasey FB, Valeriano J. Long-Term Follow Up of Combination Antimicrobial Therapy for *Chlamydia*-Induced ReA. 71st American College of Rheumatology National Annual Scientific Meeting. Boston, MA, November 6-11, 2007.
13. **Carter JD**, Kedar RP, Osorio AH, Albritton NL, Gnanashanmugam S, Valeriano J, Vasey FB, Ricca LR. MRI and Ultrasound Findings in Patients with Gout and Normal Plain Radiographs.

- 72nd American College of Rheumatology National Annual Scientific Meeting. San Francisco, CA, October 26-29, 2008. ARTHRITIS RHEUM 2008;Vol 58, No.9:S176.
14. Sterrett AG, **Carter JD**, Bateman H, Vasey F, Reddy P, Westphal L, Ahmadi S, Valeriano-Marcet J. Does “Arthur” Teach Internal Medicine Residents Joint Pattern Recognition? 72nd American College of Rheumatology National Annual Scientific Meeting. San Francisco, CA, October 26-29, 2008. ARTHRITIS RHEUM F119:50.
 15. Sterrett AG, Guthrie J, Osting V, **Carter JD**, Bateman H, Vasey F, Reddy P, Valeriano-Marcet J. Joint Injection Workshops Using Simulators to Teach Internal Medicine Residents Arthrocentesis. 72nd American College of Rheumatology National Annual Scientific Meeting. San Francisco, CA, October 26-29, 2008. ARTHRITIS RHEUM F120:50.
 16. **Carter JD**, Gerard HC, Espinoza LR, Ricca L, Valeriano J, Vasey FB, Hudson AP. An Analysis of Chlamydial Infections as the Etiology of Chronic Undifferentiated Spondyloarthritis. 72nd American College of Rheumatology National Annual Scientific Meeting. San Francisco, CA, October 26-29, 2008. ARTHRITIS RHEUM 2008;Vol 58, No.9:S2049. **Oral Presentation: Concurrent Session.**
 17. Gerard HC, Guthrie JP, Whittum-Hudson JA, **Carter JD**, Hudson AP. Functional CCR5 receptor protects arthritis patients from high synovial *C trachomatis* burden. Chlamydia Basic Research Society; March 20-23; 2009.
 18. Gerard HC, **Carter JD**, Whittum-Hudson JA, Schumacher HR, Hudson AP. Patients with reactive arthritis have ocular, not genital, serovars of *Chlamydia trachomatis* in synovial tissue. Chlamydia Basic Research Society; March 20-23; 2009.
 19. Osting VC, Rehman A, Sterrett AG, Koltz C, Reddy P, **Carter JD**, Bateman H, Ricca L, Valeriano-Marcet J. Joint Simulator Workshop as a Teaching Tool for Joint Injections: Do Rheumatology Subspecialty Residents Benefit? ACR Scientific Meeting. Philadelphia, PA. October 19-22, 2009.
 20. Rehman A, Sterrett AG, Osting VC, **Carter JD**, Bateman H, Reddy P, Ricca L, Valeriano-Marcet J. Workshop Using Simulators to Teach Medical Students Large Joint Injection. ACR Scientific Meeting. Philadelphia, PA. October 19-22, 2009.
 21. **Carter JD**, Sebba AI, Osorio AH, Albritton NL, Pfeiffer GL, Valeriano J, Vasey FB. A Safety Analysis of Oral Prednisone as a Pre-Treatment for Rituximab in Rheumatoid Arthritis. ACR Scientific Meeting. Philadelphia, PA. October 19-22, 2009.
 22. **Carter JD**, Espinoza LR, Inman RD, Sneed KB, Ricca LR, Vasey FB, Valeriano J, Stanich JA, Oszust C, Gerard HC, Hudson AP. Combination Antibiotics as a Treatment for Chronic *Chlamydia*-Induced Reactive Arthritis ACR Scientific Meeting. Philadelphia, PA. October 19-22, 2009. **Plenary Session Presentation.**
 23. Inman RD, Chiu B, Hudson AP, **Carter JD**. IL-12p70 Profiles in Antibiotic Treatment of Chlamydia-induced Reactive Arthritis (ReA). ACR Scientific Meeting. Atlanta, GA Nov 6-11, 2010. **Oral Concurrent Session Presentation.**

24. Lin J, Shetty AG, **Carter JD**. The Diagnosis of Reactive Arthritis in the Real World and Factors that Might Contribute to its Under/Misdiagnosis. ACR Scientific Meeting. Atlanta, GA Nov 6-11, 2010.
25. Rodriguez E, Sterrett AG, Bateman HR, Ricca LR, **Carter JD**, Valeriano J. "Medical Student Education in the Electronic Age: A Web-Based Virtual Teaching Tool" ACR Scientific Meeting. Atlanta, GA Nov 6-11, 2010.
26. **Carter JD**, Gerard HC, Hudson AP. *C trachomatis* is Present and Metabolically Active During the Remitting Phase in Synovial Tissues From Patients with Chronic *Chlamydia*-Induced Reactive Arthritis. *Arthritis & Rheum* 2011;63(10)[supp]:S755. ACR Scientific Meeting. Chicago, IL Nov 4-9, 2011.
27. Guthrie JP, Rehman A, Gerard HC, Stanich J, Hudson AP, **Carter JD**. The Effect of CCR5-Delta-32 Mutation on *Chlamydia*-Induced Reactive Arthritis. *Arthritis & Rheum* 2011;63(10)[supp]:S758. ACR Scientific Meeting. Chicago, IL Nov 4-9, 2011.
28. **Carter JD**, Albritton N, Zarabadi SA, Ricca LR, Valeriano-Marcet J, Vasey FB, Sebba A. A safety Analysis of Oral Prednisone as a Pre-Treatment for Rituximab in Rheumatoid Arthritis. *Arthritis & Rheum* 2011;63(10)[supp]:S876. ACR Scientific Meeting. Chicago, IL Nov 4-9, 2011.
29. Osting VC, Gonzalez J, Valeriano J, **Carter JD**. A randomized prospective open-label comparison of two Vitamin D3 repletion strategies in Vitamin D deficient patients. USF Health Research Day. Feb 24, 2012.
30. Baillargeon A, **Carter JD**. MRI Findings in Patients with Eosinophilic Fasciitis. USF Health Research Day. Feb 24, 2012.
31. **Carter JD**, Patelli M, Anderson SR, Prakash N, Aydelott R, Rodriguez EJ, Bateman H, Sterrett AG, Valeriano J, Ricca LR. An Assessment of Chronic Synovial-Based Inflammation in Gout and its Correlation with Serum Urate Levels. EULAR National Meeting. Madrid, Spain. June 15, 2013.
32. Oikonomopoulos I, **Carter JD**. Comparison of C-Reactive Protein (CRP) and Erythrocyte Sedimentation Rate (ESR) with Estimated Glomerular Filtration Rate (eGFR) in Patients with Rheumatoid Arthritis (RA). ACR Scientific Meeting. Boston, MA Nov 14-19, 2014.
33. Genovese M, Fleishmann R, Furst D, Janssen N, **Carter JD**, Dasgupta B, Pitzalis C, Vasyutin I, Kavariasu T, Krotkova A, Durez P. Improvements in Patient-Reported Outcomes with Olokizumab Treatment in Patients with Active, Moderate to Severe Rheumatoid Arthritis who had Failed Previous Anti-TNF Therapy: Results from the RA0056 Double-Blind, Randomized Controlled Study, and RA0057, Its Open Label Extension. EULAR National Meeting. London, England. June 9, 2016.

34. Gina A. Montealegre Sanchez¹, Adam Reinhardt², Paul Brogan³, Dawn C. Chapelle⁴, Hanna Kim⁴, Samantha Judd⁴, Bahar Kost⁴, Michelle O'Brien⁴, Wendy Goodspeed⁴, Robert A. Colbert⁴, Meryl Waldman⁵, Deborah L. Stone⁶, Ling Gao⁷, JA Dare⁸, Susanne Schalm⁹, Thomas L. Klausmeier¹⁰, Sara Murias¹¹, Yackov Berkun¹², Diane Brown¹³, **John D. Carter**¹⁴, Fehime K Eroglu¹⁵, A. Zlotogorski¹⁶, Philip Hashkes¹⁷, Helmut Wittkowski¹⁸, Suzanne Ramsey¹⁹, Seza Ozen²⁰, Adriana Almeida de Jesus²¹ and Raphaela Goldbach-Mansky²¹ Preliminary Response to JAK1/2 Inhibition with Baricitinib in “Candle”, “Savi” and “Candle-like” Diseases. a New Therapeutic Approach for Type I IFN Mediated Autoinflammatory Diseases. ACR Scientific Meeting. Washington D.C. Nov 12-16, 2016.
35. Figueroa-Sierra M, Cao, S, Yuanyuan L, Bateman H, **Carter JD**, Lin, YC, Cuchacovich R, Maldonado M, Valeriano-Marcet J, Montes-Rivera G. Improving Glucocorticoid Induced Osteoporosis Screening and Management in Patients with Rheumatic Diseases Using the 2017 ACR Guidelines. ACR Scientific Convergence 2020. Arthritis Rheumatol 2020; 72 (suppl 9).
36. Holguin Balbuena S, Radisic A, Goodman S, Gor S, Wood B, Shahin A, Samuel K, Mhaskar R, **Carter JD**. Clinical Outcomes of COVID-19 Vaccination and Booster in Patients with Autoimmune Inflammatory Rheumatic Disease. ACR Scientific Convergence 2022. Arthritis Rheumatol 2022; 74 (suppl 9). Chosen as an “Ignite Talk”.

Continuing Professional Education/Invited Lectures

1. *First Annual New Frontiers in Rheumatology*
CPE Course designed for Primary Care Physicians, PA’s, and ARNP’s
CPE Credit: 4 hours
April 14, 2005
Wyndham Westshore; Tampa, FL
Course Director and Lecturer
2. *Second Annual New Frontiers in Rheumatology*
CPE Course designed for Primary Care Physicians, PA’s, and ARNP’s
CPE Credit: 5 hours
September 30, 2006
Wyndham Westshore; Tampa, FL
Course Director and Lecturer
3. “Nonvertebral Fracture Efficacy: Shifting the Paradigm with a Focus on Absolute Risk Reduction.”
CPE Publication Newsletter
CPE Credit: 1 hour
Spring 2006 – Spring 2007
Sole Author
4. Practical Orthopedics and Sports Medicine for Primary Care
“Non-surgical Treatment of Arthritis”
CPE Credit: 0.5 hour
February 22, 2008
Hilton; Clearwater, FL
Lecturer

5. Florida Society of Rheumatology
“Psoriatic Arthritis: A Rash of New Treatments”
CPE Credit: 1.0 hour
July 12, 2008
Westin Diplomat, Hollywood, FL
Lecturer
6. Florida Society of Rheumatology
“Reactive Arthritis: What’s a Bug Like You Doing in a Joint Like This?”
CPE Credit: 1.0 hour
July 13, 2008
Westin Diplomat, Hollywood, FL
Lecturer
7. Tennessee Rheumatology Society
“Reactive Arthritis: What’s a Bug Like You Doing in a Joint Like This?”
CPE Credit: 1.0 hour
March 14, 2009
Embassy Suites, Nashville, TN
Lecturer
8. Takeda Pharmaceuticals, Inc
“Gout: New Imaging of an Old Disease: What have we been Missing?”
June 17, 2009
Takeda Pharmaceuticals, Chicago, IL
Lecturer for SMART Lecture Series
9. American College of Physicians – Florida Chapter
“Gout: New Advances of an old Disease”
September 11, 2009
The Tradewinds, St. Petersburg, FL
Lecturer
10. Wayne State University Rheumatology Grand Rounds
“Reactive Arthritis”
February 12, 2010
Lecturer
11. Broward General Medical Center Grand Rounds
“Non-Breaking News in Osteoporosis”
February 3, 2011
Lecturer
12. American Society of Consultant Pharmacists
“Biologics in RA: Efficacy and Safety”
Tampa, FL; June 6, 2011
Lecturer
13. American College of Rheumatology National Convention
“Reactive Arthritis: Clinical Insights and Treatment Options”
Chicago, IL. November 8, 2011
Lecturer
14. American Society of Consultant Pharmacists
“Biologics in the Elderly”
St. Petersburg, FL; May 4, 2012
Lecturer
15. Morton Plant Mease Hospital Grand Rounds
“Advances in Gout”

- Clearwater, FL May 8, 2012
Lecturer
16. European League Against Rheumatism (EULAR) International Convention
“Viable Joint Resident Microbes as Drivers of Arthritis”
Berlin, Germany. June 9th, 2012
Lecturer
17. SPARTAN/GRAPPA Regional Symposium
“Comorbidities of Psoriatic Arthritis and Ankylosing Spondylitis”
Tampa, FL. April 12th, 2015
Lecturer
18. SPARTAN/GRAPPA Regional Symposium
“Reactive Arthritis, Iritis, and Inflammatory Bowel Disease Arthritis”
Tampa, FL. April 12th, 2015
Lecturer
19. American Society of Consultant Pharmacists
“Biologics in the Elderly”
Grapevine, TX; November 8, 2019
Lecturer
20. Southeastern Rheumatology Fellowship Symposium
“Reactive Arthritis”
Tampa, FL October 23, 2022
Lecturer

Innovative Creative Projects

1. “Reactive Arthritis”
CD Presentation
Recruiting Tool for my NIH Funded International Multi-Centered Trial
Designed May 2006

IV. SERVICE

University/Local

1. Scientific Review Committee
University of South Florida
May 2002 – 2019
2. Billing Integrity Committee.
University of South Florida.
May 2004 – 2010.
3. Faculty Council
University of South Florida
August 2008 – 2010
4. PACE (Project to Advance Clinical Education) Committee.
University of South Florida.
Musculoskeletal/Dermatology Committee.
Mission: Design Curriculum for the new Mandatory 4th Year Student Skin & Bones Clerkship
Chair.
September 2004 – May 2005.

5. Committee On Research
University of South Florida College of Medicine
September 2009 – 2010.
6. Promotion and Tenure Committee
Department of Internal Medicine
University of South Morsani College of Medicine
2014 - present

Committees (Regional)

1. Florida Board of Osteoporosis.
July 2005 – July 2007.

Committees (National)

1. Official Board Reviewer for the American Board of Internal Medicine – Rheumatology. 2002 – present.
2. NIH Reviewer for RFP NIH-NIAMS-BAA-07-01
Title: Innovative Therapies for Rheumatic and Skin Diseases
October 17-18, 2006.
3. American College of Rheumatology National Meeting Abstract Reviewer
Section: Infection-Related Rheumatic Diseases
July, 2010
4. American College of Rheumatology National Meeting Section Co-Chair
Section: Infection-Related Rheumatic Diseases
2011, 2012, 2013
5. NIH Reviewer 2012/05 Council ZAR1 CNR M2
SBIR Rare Disease Grant Review
April 18, 2012

Journal Editorial Board

1. *Clinical Rheumatology* – Editor: Luis R. Espinoza, M.D.
Impact Factor: 2.037
2012 - 2020

Journal Reviewer

1. *Journal of Rheumatology* - Editor: Duncan Gordon, M.D.
Impact Factor: 3.695
2. *Annals of the Rheumatic Diseases* - Editor: Leo van de Putte, M.D.
Impact Factor: 9.111
3. *Rheumatology*
Impact Factor: 4.226
4. *Arthritis and Rheumatism* - Editor: Michael Lockshin, M.D.
Impact Factor: 7.866
5. *Seminars in Arthritis and Rheumatism* - Editors: Roy D. Altman, M.D. & Normal L. Gottlieb, M.D..
Impact Factor: 3.580
6. *Bone* - Editor: Roland Baron, M.D.
Impact Factor: 3.966

7. *Journal of Clinical Rheumatology* – Editor: H. R. Schumacher, M.D.
Impact Factor: 1.416
8. *CHEST* - Editor: Richard S. Irwin, M.D.
Impact Factor: 4.008
9. *Nature Reviews Rheumatology* – Editor: Jenny Buckland, PhD
Impact Factor: 6.448

Community Service

1. Walk for a Cure.
Arthritis Foundation Fundraiser
2004 – present
2. Arthritis Yearly Benefit
Arthritis Foundation
Update on Arthritis Lecture Series
2001 – 2009
3. Tampa General Patient Education Series
Yearly Lecture on Arthritis
2002 – present

AWARDS:

1. Winner of the First Annual Amgen Rheumatology Young Investigator Forum. Destin, Florida; September 17, 2003.
2. Florida Medical Association Distinguished Physician Award; June 30, 2006.
3. “America’s Top Physicians”; Consumers’ Research Council of America; 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023
4. “Best Doctors in America”; Best Doctors, Inc.; 2007, 2008, 2009, 2010, 2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023
5. National Institutes of Health Loan Repayment Award. July 2007 – June 2009.
6. Alpha Omega Alpha; elected 2009
7. Patients’ Choice Recognition Award; 2010, 2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022
8. America’s Most Compassionate Doctors Award; 2011, 2012, 2013, 2014, 2015, 2016
9. Tampa Bay Top Doctors: 2009 - present
10. Outstanding Faculty Research Award, USF Health; 2012
11. USF Morsani College of Medicine Press Gainey Top Performer Award; 2019 and 2022